Trial Profile
An exploration of Apatinib Plus IP solution as 2nd Line Treatment in Patients With Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Antineoplastics
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 09 Oct 2018 New trial record